Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Withdrawn 1Suspended 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Gynecologic 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 510Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
E7777 fusion protein × Lymphoid × Clear all
NCT04855253 2026-01-15

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Masonic Cancer Center, University of Minnesota

Phase 1/2 Suspended
30 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02676778 2021-07-15

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

Eisai Inc.

Phase 2 Completed
45 enrolled 28 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01355783 2013-11-18

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Eisai Inc.

Phase 3 Withdrawn
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡